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ABSTRACT
Clostridium difﬁcile is a major cause of infectious diarrhoea in hospitalised patients. Most pathogenic C.
difﬁcile strains produce two toxins, A and B; however, clinically relevant toxin A-negative, toxin B-
positive (A–B+) strains of C. difﬁcile that cause diarrhoea and colitis in humans have been isolated
worldwide. The aims of this study were to isolate and characterise A–B+ strains from two university
hospitals in Dublin, Ireland. Samples positive for C. difﬁcile were identiﬁed daily by review of ELISA
results and were cultured on selective media. Following culture, toxin-speciﬁc immunoassays, IMR-90
cytotoxicity assays and PCR were used to analyse consecutive C. difﬁcile isolates from 93 patients. Using
a toxin A-speciﬁc ELISA, 52 samples produced detectable toxin. All isolates were positive using a toxin
A ⁄B ELISA. Similarly, all isolates were positive with the cytoxicity assay, although variant cytopathic
effects were observed in 41 cases. PCR ampliﬁcation of the toxin A and toxin B genes revealed that 41 of
the previous A–B+ strains had a c. 1.7-kb deletion in the 3¢-end of the tcdA gene. Restriction enzyme
analysis of these amplicons revealed the loss of polymorphic restriction sites. These 41 A–B+ isolates
were designated toxinotype VIII by comparison with C. difﬁcile strain 1470. PCR ribotyping revealed that
all A–B+ isolates belonged to PCR-ribotype 017. A–B+ C. difﬁcile isolates accounted for 44% of the isolates
examined in this study, and appeared to be isolated more frequently in Dublin, Ireland, than reported
rates for other countries.
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INTRODUCTION
Clostridium difﬁcile is a common nosocomial
pathogen and a major cause of infectious diar-
rhoea among hospitalised patients [1,2]. Coloni-
sation with C. difﬁcile is associated with a wide
spectrum of clinical presentations, ranging from
asymptomatic carriage to fulminant pseudomem-
branous colitis [3]. Recently, several institutions
worldwide have reported an increase in the
incidence of severe disease caused by C. difﬁcile
[4–7]. This may be related to several factors,
including the changing demographics of patients
admitted to hospitals, infection control policies,
or the emergence of more virulent strains of C.
difﬁcile with increased antimicrobial resistance
[7,8] (42nd Annual meeting of the Infectious
Disease Society of America, 2004, abstract LB-2).
Two structurally similar toxins, denoted A and
B, are the main virulence determinants linked
with C. difﬁcile-associated disease (CDAD), and
most pathogenic strains of C. difﬁcile produce both
toxins (A+B+) [9,10]. The role of these toxins in the
pathogenesis of CDAD has been well-described
[10]. Both toxin A and toxin B are pro-inﬂamma-
tory, cytotoxic and enterotoxic in the human colon
[11,12]. These toxins are encoded by two genes,
tcdA and tcdB, that map to a 19.6-kb pathogenicity
locus (PaLoc) containing additional regulatory
genes [13]. C. difﬁcile isolates with varying genetic
modiﬁcations within the PaLoc have been des-
cribed [14,15]. These include variant C. difﬁcile
isolates that produce functional toxin proteins
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TcdA and TcdB, and toxin-variant isolates that
fail to produce detectable toxins [14,16–18].
Toxin A-negative, toxin B-positive (A–B+)
C. difﬁcile strains were thought originally to be
non-pathogenic. However, several recent reports
have demonstrated their clinical importance
[19–21]. Although outbreaks caused by A–B+
C. difﬁcile are rare, several sporadic cases of
infection and cases of pseudomembranous colitis
(PMC) have been documented from several coun-
tries [20–23], and estimated prevalence rates of
A–B+ C. difﬁcile strains vary widely [24].
To date, four A–B+ strain types have been
reported. Two toxinotypes, type VIII (strain 1470)
and type X (strain 8864) have been well-described
[25,26]. Both of these strains are truncated in the
3¢-region of the repetitive domain of tcdA. In
addition, both strains have alterations in their
tcdB genes whereby restriction fragment length
polymorphisms (RFLPs) give rise to altered glu-
cosylation of RHO proteins and induce a differ-
ential cytopathic effect (CPE) when variant toxin
B is compared with wild-type toxin B from A+B+
strains [27]. More recently, two additional A–B+
toxinotypes (type XVI and type XVII) have been
described in Asia [15]. The molecular mechanism
responsible for the absence of toxin A production
in these newer toxinotypes has not yet been
elucidated. Of the four A–B+ strain types, toxino-
type VIII is considered to be the most clinically
signiﬁcant, and has been associated with the three
reported outbreaks involving A–B+ C. difﬁcile
[19,20].
The present study reports, for the ﬁrst time, the
isolation of A–B+ C. difﬁcile (PCR ribotype 017,
toxinotype VIII) from a number of healthcare
settings in Dublin, Ireland.
MATERIALS AND METHODS
C. difﬁcile strains and patients
Between 1 February and 31 July 2004, all C. difﬁcile toxin-
positive faecal samples from new cases of C. difﬁcile diarrhoea
at two major university-afﬁliated teaching hospitals in Dublin
(St Vincent’s University Hospital and the Mater Misericordiae
University Hospital) were investigated. These hospitals have
570 and 490 beds, respectively. Both hospitals test all samples
for which a C. difﬁcile toxin assay is requested, in addition to
testing non-requested liquid stool specimens from all in-
patients and outpatients aged >65 years. The Premier toxin
A ⁄B ELISA (Meridian Bioscience Inc., Cincinnati, OH, USA),
which detects both toxins A and B, was used in both
laboratories for C. difﬁcile toxin detection. Incidence rates at
both hospitals were 7 ⁄ 1000 patient admissions for the period
of the study. While several repeat samples were collected from
patients throughout the investigation, only the ﬁrst isolate
from each patient was included for analysis in this study. In
addition, 17 random samples from a third university hospital,
collected during the months of February and May, were
investigated, as well as six random samples acquired from
three general practice surgeries and three nursing homes.
Of 85 new C. difﬁcile cases in the two university hospitals
during the study period, 15 samples were unavailable for
culture because of insufﬁcient remaining specimen following
routine microbiological investigations. The remaining 70 faecal
samples were cultured on Cyloserine-Cefoxitin-Fructose Agar
(CCFA) (LIP, Galway, Ireland). Identiﬁcation of C. difﬁcile was
conﬁrmed by morphology, Gram’s stain, odour and UV
ﬂuorescence, and latex agglutination (Microgen Bioproducts,
Camberley, UK). C. difﬁcile controls included strains VPI 10463
(A+B+), 630 (A+B+), 57267 (A+B+), 1470 (A–B+) and 8864 (A–B+).
A non-toxigenic strain (R10567) served as a negative control in
all experiments.
Detection of C. difﬁcile toxins
Toxin-speciﬁc immunoassays and cytotoxicity assays were
used to determine in-vitro toxin production. C. difﬁcile isolates
were inoculated into brain heart infusion (BHI) broth (Oxoid,
Basingstoke, UK) and were cultured anaerobically for 48 h.
Broth cultures were centrifuged, after which the supernatants
were ﬁltered through 0.2-lM Acrodisc syringe ﬁlters (Pall
Corp., Portsmouth, UK) and stored at –20C for up to
3 months before analysis of toxin production. Toxin A was
detected using the C. difﬁcile Tox A ELISA (Tech Laboratory,
Blacksburg, VA, USA) according to the manufacturer’s
instructions. The C. difﬁcile Tox A ⁄B ELISA (Tech Laboratory)
was used to detect the presence of toxin A and ⁄or toxin B.
Toxin B was detected using a tissue culture cytotoxin assay
and the IMR-90 ﬁbroblast cell line (CAMR, Salisbury, UK). In
brief, ﬁltered bacterial supernatants were added to IMR-90
monolayers, after which cytotoxicity was determined by
examining for cell rounding after 24 and 48 h. The speciﬁcity
of the CPE was conﬁrmed by neutralisation with Clostridium
sordellii antitoxin (Tech Laboratory).
Molecular analysis of tcdA and tcdB
The genes for toxins A and B, tcdA and tcdB, were character-
ised by PCR as described previously [14,28]. All primers were
synthesised commercially by MWG Biotech (Ebersberg, Ger-
many). Genomic DNA was puriﬁed from overnight Schaedler
broth cultures of C. difﬁcile using the Wizard Genomic DNA kit
(Promega, Madison, WI, USA), followed by quantiﬁcation of
template DNA using the PicoGreen ds DNA Quantitation kit
(Molecular Probes, Eugene, OR, USA). Primer sequences and
restriction enzymes used for PCR and RFLP analysis, respect-
ively, are shown in Table 1. The relative locations of the
toxinotyping primers on the C. difﬁcile PaLoc are shown in
Fig. 1(A). All PCRs were performed on a Perkin-Elmer 2400
Thermal Cycler (Applied Biosystems, Foster City, CA, USA) in
ﬁnal reaction volumes of 50 lL using conditions described
previously [28,29]. Ampliﬁed products were visualised fol-
lowing electrophoresis on conventional agarose 1.5% w ⁄v gels
stained with ethidium bromide 0.5 mg ⁄mL in 1 · TBE buffer
(89 mM Tris base, 89 mM boric acid, 2 mM EDTA). Gels were
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visualised and photographed using the Gel Doc 2000 system
(Bio-Rad, Hercules, CA, USA). Two PCR products, denoted A3
and B1, were selected for restriction enzyme analysis with
EcoRI and HincII (Promega). Digests were visualised as
described previously and strain toxinotypes were assigned
according to the restriction digest patterns obtained.
16–23S PCR ribotyping
PCR ribotyping was performed as described by Stubbs et al.
[30] with minor modiﬁcations. DNA ﬁngerprints were stored
as tagged image ﬁle format (TIFF) ﬁles and imported into
BioNumerics software v.4.0 (Applied Maths, Sint-Martens-
Latem, Belgium). Dendrograms were created using the DICE
coefﬁcient and the unweighted pair group method with
arithmetic mean (UPGMA) for cluster correlation using default
settings.
RESULTS
Between February and August 2004, C. difﬁcile
isolates were cultured from the faeces of 93
symptomatic adult patients. Initially, these iso-
lates were examined for in-vitro production of
toxins A and B. Using the Toxin A ELISA, 52
isolates produced detectable toxin A (Table 2).
The remaining 41 isolates tested negative.
Table 1. Primers and restriction
enzymes used in this studyPrimer Primer sequence
Size (bp)
for VPI 10463
Target gene
(region)
Restriction
enzyme
NK9 5’-CCACCAGCTGCAGCCATA-3’ tcdA (A3)
NK11 5’-TGATGCTAATAATGAATCTAAAATGGTAAC-3’ 1200
A1C 5’-GGAGGTTTTTATGTCTTTAATATCTAAAGA-3 tcdA (A1)
A2N 5’-CCCTCTGTTATTGTAGGTAGTACATTTA-3’ 3100
A2C 5’-TAAATGTACTACCTACAATAACAGAGGG-3’ tcdA (A2)
A3N 5’-CTTGTATATAAATCAGGTGCTATCAATA-3’ 2000
A3C 5’-TATTGATAGCACCTGATTTATATACAAG-3’ tcdA (A3) EcoR1
A4N 5’-TTATCAAACATATATTTTAGCCATATATC-3’ 3100
B1C 5’-AGAAAATTTTATGAGTTTAGTTAATAGAAA-3’ tcdB (B1) HincII
B2N 5’-CAGATAATGTAGGAAGTAAGTCTATAG-3’ 3100
B2C 5’-ATAGACTTACTTCCTACATTATCTGAA-3’ tcdB (B2)
B3N 5’-CATCTGTATAAATATTTGGTGAAATTAC-3’ 2000
B3C 5’-AATTTCACCAAATATTTATACAGATG-3’ tcdB (B3)
B4N 5’-ATTTAACATATTTTTATCTATTCA-3’ 2000
(A)
(B)
(C)
Fig. 1. (A) Schematic representation of the Clostridium difﬁcile pathogenicity locus (PaLoc). The relative locations of the
primer sequences (Table 1) used to amplify regions of tcdA and tcdB are shown. (B) Example of an agarose 1.5% w ⁄ v gel
showing the amplicons from the A3 PCR assay using primer pair A3C and A4N targeted at the repeated sequences of tcdA.
The arrows, in descending order, correspond to the A+B+ amplicon (3100 bp) and the A–B+ amplicon (1500 bp) (see
Tables 1 and 2). Lanes: M, 1-kb DNA ladder; 1, (A+B+) VPI 10463; 2–6, A–B+ clinical isolates; 7, A–B+ control strain F-1470;
8–11, A+B+ clinical isolates; 12, A–B– control. (C) Example of an agarose 1.5% w ⁄ v gel showing restriction digest patterns of
the A3 fragments from (A) following digestion with EcoRI. Lane assignment as indicated for (B). A–B+ C. difﬁcile strains
only show the RFLPs indicated by the ﬁlled arrow.
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However, when the Toxin A ⁄B ELISA was used,
toxin production was detected with all isolates.
Furthermore, all isolates induced a CPE when
investigated using the cell culture cytotoxicity
assay (Table 2). The CPE observed for the 41
isolates that were negative in the toxin A ELISA
was atypical, demonstrating complete cell round-
ing of the ﬁbroblast body with no cytoplasmic
extensions (data not shown).
All C. difﬁcile isolates were investigated by
amplifying the tcdA gene with primer pair NK
9-NK 11 to detect genetic alteration(s) in the
3’-region (Table 1). Forty-one isolates carried a
deletion and yielded a shorter amplicon (700 bp)
than that produced from the reference strain VPI
10463 (1200 bp) (Fig. 1(A), Table 2). These unique
isolates were classiﬁed as toxin A–B+ and were
evaluated further by toxinotyping (PCR-RFLP),
involving six PCRs designed to amplify the
complete tcdA (A1, A2, A3) and tcdB (B1, B2, B3)
genes (Fig. 1(A)) [29,31]. In all 41 cases, there was
a c. 1.7-kb deletion in the 3’-region of the tcdA
gene (denoted by the open bar in Fig. 1(A); see
also Fig. 1(B) and Table 2). Ampliﬁcation of
selected domains within the A1 and A2 regions
of tcdA and the B1, B2 and B3 regions of tcdB
showed no alterations in amplicon size in com-
parison with the control strain 10463 (A+B+)
(Table 2).
Restriction enzyme digests of the tcdA locus
revealed the loss of some restriction sites in these
A–B+ strains. Furthermore, the A3 amplicon could
not be digested by EcoRI (Fig. 1(C)). Similarly,
HincII digestion proﬁles of the B1 product were
consistent with the loss of one or more HincII
restriction sites (denoted by the hatched bar in
Fig. 1(A); see also Fig. 2). Based on these restric-
tion patterns, all 41 isolates were designated as
toxinotype VIII, according to the toxinotyping
scheme of Rupnik et al. [14]. The C. difﬁcile isolates
were analysed by 16–23S PCR ribotyping, produ-
cing DNA banding patterns of 10–15 bands,
ranging in size from c. 200–1500 bp. Analysis of
the banding patterns obtained for the 41 A–B+
isolates showed clonality, with identical banding
patterns observed (data not shown). Ribotyping
analysis revealed nine distinct ribotypes among
the 35 A+B+ isolates (Table 3). There were seven
different ribotypes among the 23 A+B+ isolates
from hospital A, and seven ribotypes among the
12 A+B+ isolates from hospital B (data not shown).
There were ﬁve ribotypes that were common to
both university hospitals, while two distinct
ribotyping patterns were found in one hospital
only (data not shown).
Toxin A–B+ C. difﬁcile strains were isolated from
44% of the patients in this study. The distribution
of the A–B+ isolates in the two university hospitals
is summarised in Table 3. A–B+ C. difﬁcile strains
were recovered from patients in these two uni-
versity hospitals, as well as from patients in a
Table 2. Summary of results for
detection of A)B+ Clostridium difﬁcile
No. (%) of samples
Toxigenic
status
Toxin
A ELISA
Toxin
A+B ELISA
Cell culture
cytotoxicity Assay
Primer pair and amplicon size (kb)
NK 9-11 A1 A2 A3 B1 B2 B3
52 (56) A+B+ + + + 1.2 3.1. 2.0 3.1 3.1 2.0 2.0
41 (44) A-B+ - + +a 0.7 b 3.1. 2.0 1.5 b 3.1 2.0 2.0
aVariant cytopathic effect observed.
bShorter amplicon caused by deletion in tcdA.
Fig. 2. Amplicons and RFLPs in the tcdB1 locus. Example
of an agarose 1.5% w ⁄ v gel showing the restriction
patterns of B1 PCR amplicons following restriction digest
with HincII. Lanes: 1 and 6, A–B+ Clostridium difﬁcile; 2 and
3, A+B+ C. difﬁcile; 5, C. difﬁcile VPI 10463; and M, 100-bp
molecular size marker. A–B+ C. difﬁcile strains show RFLPs
indicated by the ﬁlled arrow.
Table 3. Distribution of A+B+ and A-B+ Clostridium difﬁcile
isolates in two university hospitals in Dublin, Ireland
Hospital
Institution Identiﬁer A B
Number of isolates 40 30
No. A+B+ C. difﬁcile
% per institution
23
(57)
12
(40)
No of ribotypes 7 7
No. A-B+ C. difﬁcile
% per institution
17
(43)
18
(60)
No of ribotypes 1 1
A, Mater Misericordiae University Hospital.
B, St Vincent’s University Hospital.
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third university hospital and from three commu-
nity specimens. In total, 75% (70 ⁄ 93) of all the
isolates examined were cultured from patients
attending the two large university hospitals
(Table 3), where the prevalence rates for A–B+
C. difﬁcile isolates were 43% and 60%, respect-
ively. Overall, 35 (50%) of 70 patients at the two
university hospitals were infected with A–B+
C. difﬁcile (Table 3).
DISCUSSION
Toxin A-negative, toxin B-positive (A–B+)
C. difﬁcile has been isolated from many institu-
tions in several countries on four continents [24].
Varying prevalence rates have been reported: a
rate of 2% was reported in a multicentre study in
the USA following analysis of C. difﬁcile isolates
from six clinical settings [32]; in the UK, a
prevalence rate of 3% was found among 43
isolates from nine of 35 hospitals that submitted
strains for typing to the Anaerobic Reference
Laboratory in Cardiff [33]; and in France, a rate of
3% for isolates from 25 different hospitals in Paris
was reported [34]. In contrast, A–B+ prevalence
rates as high as 39% have been described in a
Japanese study [35], and a recent study in Israel
reported A–B+ C. difﬁcile rates of 56% [36].
C. difﬁcile is cultured in 55% of European
laboratories, but culture rates per country vary
considerably, from 20% to 100% [37]. C. difﬁcile is
not cultured routinely in Irish hospitals, giving
rise to a knowledge gap concerning the molecular
epidemiology of Irish C. difﬁcile strain types and
the prevalence of A–B+ C. difﬁcile. Limited typing
of isolates from previous outbreaks at two of the
participating institutions in the present study
suggested the presence of A–B+ C. difﬁcile (PCR
ribotype 017) in both hospitals. Between March
1999 and January 2000, six (14%) of 42 isolates
from the third university hospital were A–B+,
while nine (60%) of 15 isolates from the Mater
Misericordiae University hospital were A–B+
between March 2001 and March 2003 (J. Brazier,
personal communication).
The overall frequency of A–B+ C. difﬁcile isolates
in this study was higher (44%) than non-outbreak
rates reported for other countries [24]. This may
reﬂect the collection of isolates analysed. A
limitation of the present study was that 75% of
the isolates investigated were from two university
hospitals, in which the toxin variant strain
accounted for 43% and 60%, respectively, of the
isolates collected. These data may be biased by the
local epidemiology of C. difﬁcile in these institu-
tions, e.g., persistence of a clonal strain from an
outbreak that is known to have occurred during
2003 in the Mater Misericordiae hospitals, where
the incidence rate peaked at 20 cases ⁄ 1000 patient
admissions. However, to our knowledge, no
outbreak of A–B+ C. difﬁcile occurred at St Vin-
cent’s University hospital. Furthermore, analysis
of 50 C. difﬁcile isolates collected at this hospital
between 1997 and 1998 revealed that 65% of
isolates characterised were clonal A+B+ strains
and that A–B+ C. difﬁcile were not prevalent in this
hospital during that period (personal unpub-
lished results). However, it is possible that A–B+
C. difﬁcile may have replaced the predominant
A+B+ strain types in recent years. Similarly, an
Argentinian hospital reported that A–B+ strains
replaced A+B+ strains completely over a 4-year
period, with no variation in incidence or clinical
presentation of CDAD [38].
A further possible limitation of the present
study was the random nature with which samples
were collected from the third university hospital,
GP surgeries and nursing homes. However, these
additional data conﬁrmed the presence of these
variant isolates in additional healthcare settings.
All isolates were collected in a non-epidemic
setting, as demonstrated by the stable incidence
rates of C. difﬁcile at the two major centres;
however, the reasons for clonal spread and
persistence of these variant strain types remain
to be determined.
A recent survey by the ESCMID Study Group
on C. difﬁcile found that 58% of laboratories
surveyed in eight European countries use diag-
nostic methods for C. difﬁcile that can detect only
toxin A [37]. The hospitals collaborating in the
present study used diagnostic methods that
detect both toxin A and toxin B; it is therefore
unlikely that any cases of toxin-variant C. difﬁcile
would not have been detected. Failure to use
standardised C. difﬁcile diagnostic methods that
detect both toxin A and B could lead to signiﬁcant
under-reporting of C. difﬁcile. This is of particular
concern in countries in which the prevalence of
toxin A–B+ C. difﬁcile strains is known to be high.
Furthermore, outbreaks described previously
have documented an increased severity of
C. difﬁcile disease associated with these A–B+
isolates; the ability to clearly discriminate
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between variant and non-variant C. difﬁcile there-
fore has direct clinical relevance in terms of
infection control management [19,20]. Standard-
ised approaches to the investigation of C. difﬁcile
are essential in order to increase understanding of
the factors leading to institutional outbreaks of
C. difﬁcile.
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